2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
09:30 a.m. - 11:00 a.m.
MCCNO - 217-219
Treatment Considerations, Biological Therapies, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Non-Biological Therapies, Anticoagulant Drugs, Chemotherapy, Adverse Events, Biological Processes, CHIP, Diseases, Bleeding and Clotting, Thromboembolism, Thrombotic Disorders, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, ALL, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Registries, Study Population, Human, Adult, Pediatric
PAPER

477 Inflammatory vulnerability precedes venous thromboembolism after CAR T-cell therapy for B-cell lymphoma

Thomas Francis Fusillo, DO, MS, MHA, Mohammad Alhomoud, MD2, David Nemirovsky, MS3, Linus Kruk, MD4, Meitar Abu5, Yara Abu Ahmad, MD6, Ali Abed Al Wahad, MD7, Kai Rejeski, MD8, Limor Cohen, PhD9, Parastoo B. Dahi, MD10, Lorenzo Falchi, MD11, Uri Greenbaum, MD12, Kayleen Shi13, Tobias Tix, MD14, Jennifer Kimberly Lue, M.D.15, Ahmad Mruwat16, Dana Yehudai-Ofir, MD17, Anat Rabinovich, MD18, Marion Subklewe I, MD19, Craig Sauter, MD20, Michael Scordo, MD21, Gunjan L. Shah, MD, MS22, Gilles Salles I, MD, PhD23, Sarah Samorodnitsky, PhD24, Maria Lia Palomba, MD25, Jae H Park, MD26, Miguel-Angel Perales, MD27, Veit Leonhard Buecklein, MD, PhD28, Jeffrey Zwicker, MD29, Ofrat Beyar-Katz, MD, PhD30, Roni Shouval Jr, MD, PhD31, Avi Leader, MD32
1 Memorial Sloan Kettering Cancer Center, New York, New York, United States
2 Memorial Sloan Kettering Cancer Center, New York, New York, United States, Memorial Sloan Kettering Cancer Center, New York, New York, United States
3 Memorial Sloan Kettering Cancer Center, New York, New York, United States
4 LMU University Hospital, Munich, Germany
5 Ben-Gurion University of the Negev, Beer Sheva, Israel
6 Rambam Health Care Campus, Haifa, Israel
7 Rambam Health Care Campus, Haifa, Israel
8 LMU University Hospital, Munich, Germany
9 Ben-Gurion University of the Negev, Beer Sheva, Israel
10 Memorial Sloan Kettering Cancer Center, New York, New York, United States
11 Memorial Sloan Kettering Cancer Center, New York, New York, United States
12 Soroka University Medical Center, Beer Sheva, Israel
13 LMU University Hospital, Munich, Germany
14 LMU University Hospital, Munich, Germany
15 Memorial Sloan Kettering Cancer Center, New York, New York, United States
16 Rambam Health Care Campus, Haifa, Israel
17 Rambam Health Care Campus, Haifa, Israel
18 Soroka University Medical Center, Beer Sheva, Israel
19 LMU University Hospital, Munich, Germany
20 Memorial Sloan Kettering Cancer Center, New York, New York, United States
21 Memorial Sloan Kettering Cancer Center, New York, New York, United States
22 Memorial Sloan Kettering Cancer Center, New York, New York, United States
23 Memorial Sloan Kettering Cancer Center, New York, New York, United States
24 Memorial Sloan Kettering Cancer Center, New York, New York, United States
25 Memorial Sloan Kettering Cancer Center, New York, New York, United States
26 Memorial Sloan Kettering Cancer Center, New York, New York, United States
27 Memorial Sloan Kettering Cancer Center, New York, New York, United States
28 LMU University Hospital, Munich, Germany
29 Memorial Sloan Kettering Cancer Center, New York, New York, United States
30 Rambam Health Care Campus, Haifa, Israel
31 Memorial Sloan Kettering Cancer Center, New York, New York, United States, Memorial Sloan Kettering Cancer Center, New York, New York, United States
32 Memorial Sloan Kettering Cancer Center, New York, New York, United States
Background: Inflammation and coagulation are tightly interconnected. Chimeric antigen receptor (CAR) T-cell recipients enter therapy with varying degrees of tumor- and host-related inflammation and may develop marked immune activation after infusion, creating a potentially distinct thromboinflammatory state. However, whether these inflammatory states contribute to post–CAR T-cell thrombosis remains unknown. We conducted a multicenter study to define the incidence and prognostic impact of early venous thromboembolism (VTE) after CAR T-cell therapy for B-cell lymphoma and examine its relationship with baseline inflammatory vulnerability and treatment-emergent immune toxicities.
 
Methods: This is an international multicenter retrospective study of adults with large B-cell lymphoma (LBCL), mantle cell lymphoma (MCL), or follicular lymphoma (FL) treated with commercially available CD19-directed CAR T-cell products from 2017-2026. Patients were followed from CAR T-cell infusion through day 90 and data were captured via manual chart review. The cumulative incidence of VTE was estimated at days 30 and 90 with death, relapse, and change of therapy as competing events. The effects of baseline clinical, disease, and laboratory variables obtained before lymphodepletion were estimated using a cause-specific Cox proportional hazards model. The CAR-HEMATOTOX score (Rejeski et al. Blood 2021), integrating blood counts, C-reactive protein (CRP), and ferritin, was treated as a composite measure of pre-infusion hematologic and inflammatory vulnerability. Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) were included as time-dependent covariates. The association between VTE and overall survival (OS) was evaluated using VTE within 90 days as a time-dependent exposure.
 
Results: We included 893 patients from 4 centers. Median age was 66 years (interquartile range [IQR], 57–73), 62% were male, and 59% had a Karnofsky performance status (KPS) <90. Diagnoses included LBCL (82%), MCL (11%), and FL (7%). CAR T-cell products included axi-cel (43%), liso-cel (33%), tisa-cel (17%), and brexu-cel (7%). Prior VTE was present in 15% of patients, and, among 691 patients with available data, 57% had a CAR-HEMATOTOX score ≥2. The median follow-up was 26 months (95% CI, 24-27), and the median overall survival was 41 months (95% CI, 31-60).
 
VTE occurred in 30 patients by day 30 and in 39 by day 90, corresponding to cumulative incidences of 3.4% (95% CI, 2.3–4.7) and 4.5% (95% CI, 3.2–6.0), respectively. Among the 39 VTEs, 27 (69%) were upper-extremity deep vein thromboses (DVTs), including 18 (67% of upper extremity DVTs) catheter-associated events, 6 (15%) were lower-extremity DVTs, and 6 (15%) were pulmonary emboli. When analyzed as a time-dependent covariate, VTE was associated with an increased risk of death (HR 1.99; 95% CI 1.35-2.93).
 
In univariable analysis, prior VTE (HR, 2.30; 95% CI, 1.14–4.62), CAR-HEMATOTOX score ≥2 (HR, 2.15; 95% CI, 1.00–4.63), and KPS <90 (HR, 2.38; 95% CI, 1.13–5.04) were associated with increased 90-day VTE risk. Within the CAR-HEMATOTOX construct, the association was driven by the inflammatory biomarkers CRP (P=0.008) and ferritin (P=0.044). Age, body mass index, lymphoma subtype, pre-infusion disease status, and CAR T-cell product were not associated with VTE. CRS and ICANS (all grades) occurred in 78% and 35% of patients at median times of 2 days (IQR, 1–4) and 6 days (IQR, 4–9), respectively. When modeled as time-dependent exposures, both CRS (HR, 2.05; 95% CI, 0.89–4.71; P=0.073) and ICANS (HR, 1.92; 95% CI, 0.97–3.83; P=0.070) showed nonsignificant trends toward increased VTE risk.
 
Conclusions: In this largest multicenter international cohort study to date, VTE affected 4.5% of patients by day 90 and was associated with a two-fold increase in mortality. HEMATOTOX score ≥2 and elevated CRP and ferritin at lymphodepletion were associated with VTE, and CRS and ICANS showed a concordant trend. These findings suggest a link between inflammatory activation and early VTE risk after CAR-T and support further evaluation of lymphodepletion biomarkers to guide risk-adapted thromboprophylaxis.
Thomas Francis Fusillo, DO, MS, MHA: Syndax Pharmaceuticals - Current equity holder in publicly-traded company; Revolution Medicines - Current equity holder in publicly-traded company